Company intelligence / Profile preview

Raven Biotechnologies, Inc.

South San Francisco, California, United States

Ownership: Private
Development stage: Preclinical

Overview

Raven developed a proprietary platform for the discovery and development of monoclonal antibody therapeutics targeting novel antigens on the surface of tumor and stem cells. Its lead product candidate RAV12 targeted adenocarcinomas and entered clinical development. The company built an extensive library (>1,300) of mAbs with multiple candidates identified for major solid tumors. In 2008 it was acquired by MacroGenics to complement their oncology pipeline

Therapeutic areas: Oncology
Modalities: monoclonal antibodies (mAbs)
Industry: Biotech

Partnerships

ImmunoGen – collaboration for therapeutic MAbs in ovarian cancerMonogram Biosciences – collaboration to advance diagnostic technologies using VeraTag™ platformBioprocessing Technology Institute – collaboration on stem cell antibody discovery with shared rights depending on application area

Beyond the preview

Go deeper on Raven Biotechnologies, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Raven Biotechnologies, Inc..

Explore the full profile